EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%

dc.contributor.authorSezer, A.
dc.contributor.authorKilickap, S.
dc.contributor.authorGumus, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGogishvili, M.
dc.contributor.authorTurk, H. M.
dc.contributor.authorCicin, I.
dc.contributor.authorBentsion, D.
dc.contributor.authorGladkov, O.
dc.contributor.authorClingan, P.
dc.contributor.authorSriuranpong, V.
dc.contributor.authorRizvi, N.
dc.contributor.authorLi, S.
dc.contributor.authorLee, S.
dc.contributor.authorGullo, G.
dc.contributor.authorLowy, I.
dc.contributor.authorRietschel, P.
dc.contributor.orcID0000-0002-6445-1439en_US
dc.contributor.researcherIDAAD-2667-2020en_US
dc.date.accessioned2021-04-28T10:48:21Z
dc.date.available2021-04-28T10:48:21Z
dc.date.issued2020
dc.description.sponsorshipEuropean Soc Med Oncolen_US
dc.identifier.endpageS1183en_US
dc.identifier.issn0923-7534en_US
dc.identifier.startpageS1182en_US
dc.identifier.urihttps://www.annalsofoncology.org/article/S0923-7534(20)42367-1/pdf
dc.identifier.urihttp://hdl.handle.net/11727/5789
dc.identifier.volume31en_US
dc.identifier.wos000573469102683en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.annonc.2020.08.2285en_US
dc.relation.journalANNALS OF ONCOLOGYen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleEMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%en_US
dc.typeconferenceObjecten_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PIIS0923753420423671.pdf
Size:
106.37 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: